A new study found patients with early RA had increased membrane and soluble CD64. After receiving anti-rheumatic therapy, patients’ symptoms and CD64 levels decreased, suggesting CD64 is an RA biomarker…
Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia
A new study suggests that patients diagnosed with RA as well as dyslipidemia may benefit from more aggressive antirheumatic therapy. (posted Oct. 3, 2013)